<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840526</url>
  </required_header>
  <id_info>
    <org_study_id>SUM-PSK-1</org_study_id>
    <nct_id>NCT02840526</nct_id>
  </id_info>
  <brief_title>Thoracic Paravertebral Block in Pain Management After Renal Surgery</brief_title>
  <official_title>Thoracic Paravertebral Block in Postoperative Pain Management After Renal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silesian University of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silesian University of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The objective of the study was to assess the usefulness of ThPVB in postoperative&#xD;
      pain management after open renal resection surgery.&#xD;
&#xD;
      Design, setting, participants: It was a prospective, randomised, open label study held in a&#xD;
      university hospital between 08.2013-12.2014. 58 Patients enrolled in the study were scheduled&#xD;
      for elective open renal surgery (open nephrectomy or open nephron-sparing surgery) and&#xD;
      randomised into two groups - group PVB (n=27) and group GEN (n=31).&#xD;
&#xD;
      Interventions: PVB group received preoperative ThPVB with 0,5% bupivacaine followed by&#xD;
      general anaesthesia. GEN group received standard general anaesthesia. Both groups were&#xD;
      treated postoperatively with oxycodone IV PCA (patient controlled analgesia) combined with&#xD;
      non-opioid analgesics as rescue drugs. The investigators recorded pain severity in VAS,&#xD;
      oxycodone requirement in time points, total oxycodone requirement, and sedation levels&#xD;
      throughout the first 48h. The investigators measured opioid related adverse events 24 and 48&#xD;
      h postoperatively and patients satisfaction 48h postoperatively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In PVB group before the induction of general anaesthesia a single shot thoracic paravertebral&#xD;
      blockade was performed. ThPVB was performed on Th7-Th10 level, approximately 2,5 - 3 cm&#xD;
      lateral from the top of the spinous process with prior ultrasound control of the depth of the&#xD;
      transverse process and the pleura. To make the procedure safer the investigators used&#xD;
      peripheral nerve stimulation with an isolated 10 cm needle with a start current of 2,5 mA.&#xD;
      The needle was inserted until visible muscle activity from intercostal muscles appeared, with&#xD;
      a current of 0,5-0,3mA (paravertebral space identification). Next 0,3 ml kg-1 0,5% plain&#xD;
      bupivacaine was injected after negative aspiration for air and blood. The efficacy of the&#xD;
      blockade was checked after 20 minutes with cold saline.&#xD;
&#xD;
      In both groups, PVB and GEN general anaesthesia was induced with midazolam 0,1 mgkg-1,&#xD;
      propofol 2 mgkg-1, cis-atracurium 0,15 mgkg-1 and fentanyl 1,5 µgkg-1. Patients were&#xD;
      intubated with a standard single lumen tracheal tube. Anaesthesia was maintained with 1 MAC&#xD;
      (Minimal Alveolar Concentration) sevoflurane. For surgical analgesia the investigators used&#xD;
      fractional doses of fentanyl 1-3 mg kg-1 if HR (heart rate) or MBP (mean blood pressure)&#xD;
      raised above 20% of basal values. Waking up from anaesthesia was in a post-anaesthesia care&#xD;
      unit.&#xD;
&#xD;
      Postoperative pain management schedule was identical in both groups. After the surgery, if&#xD;
      pain appeared, the patient was given oxycodone i.v. titrated to achieve acceptable analgesia&#xD;
      level or until side effects appeared. Every patient received a PCA (Patient controlled&#xD;
      analgesia) device with a 1 mgml-1 concentration oxycodone solution with a programmed single&#xD;
      bolus dose of 1 mg and a lockout time of 5 minutes. Additionally, patients were given 1g i.v.&#xD;
      paracetamol every 6 hours and 100 mg of i.v. ketoprofen every 12 hours.&#xD;
&#xD;
      For 48 h postoperatively, the investigators monitored HR, SBP (systolic blood pressure) , DBP&#xD;
      (diastolic blood pressure), sedation level in Ramsay scale, pain intensity at rest in VAS&#xD;
      (visual analogue score) scale, oxycodone requirement in pre-selected time points and total&#xD;
      oxycodone requirement. The investigators also recorded opioid-related adverse events 24 and&#xD;
      48 h postoperatively in OBAS scale and patients' satisfaction regarding postoperative&#xD;
      analgesia 48 h postoperatively in Likert scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in total amount of oxycodone needed in 48 hours after surgery</measure>
    <time_frame>48 hours postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in prevalence of opioid related adverse events in OBAS scale</measure>
    <time_frame>24 hours, 48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in pain level in VAS scale</measure>
    <time_frame>48 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in level of sedation assessed in Ramsay scale</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in patient satisfaction level assessed in Likert scale</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>PVB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thoracic paravertebral blockade PVB (preoperatively) Bupivacaine WZF Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paravertebral blockade (PVB)</intervention_name>
    <description>preoperative ThPVB performed unilaterally at Th10 level</description>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sopodorm</intervention_name>
    <description>midazolam 0,1 mgkg-1 intravenously (anesthesia induction)</description>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol WZF</intervention_name>
    <description>propofol 2 mgkg-1intravenously (anesthesia induction)</description>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimbex</intervention_name>
    <description>cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)</description>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl WZF</intervention_name>
    <description>fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)</description>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevorane</intervention_name>
    <description>sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance</description>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intubation</intervention_name>
    <description>Intratracheal intubation with a single lumen endotracheal tube</description>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxynorm</intervention_name>
    <description>1 mgml-1 concentration oxycodone solution intravenously</description>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol Kabi</intervention_name>
    <description>1g paracetamol intravenously every 6 hours</description>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketonal</intervention_name>
    <description>100 mg ketoprofen intravenously every 12 hours</description>
    <arm_group_label>GEN group</arm_group_label>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine WZF</intervention_name>
    <description>0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)</description>
    <arm_group_label>PVB group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age 18-75&#xD;
&#xD;
          -  Scheduled for elective open nephrectomy or NSS&#xD;
&#xD;
          -  Gave written consent&#xD;
&#xD;
          -  BMI 19-30&#xD;
&#xD;
          -  ASA status I-III&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Presence of chronic pain&#xD;
&#xD;
          -  Chronic mental conditions (depression)&#xD;
&#xD;
          -  Contraindications for PVB&#xD;
&#xD;
          -  Chest or spine deformations&#xD;
&#xD;
          -  Infection in planned site of PVB&#xD;
&#xD;
          -  Allergies for drugs used in the study&#xD;
&#xD;
          -  Cancer invading chest wall&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanna Misiolek, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical School of Silesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 SUM Zabrze</name>
      <address>
        <city>Zabrze</city>
        <state>Slaskie</state>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Silesian University of Medicine</investigator_affiliation>
    <investigator_full_name>Maja Copik</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>PVB</keyword>
  <keyword>PCA</keyword>
  <keyword>nephrectomy</keyword>
  <keyword>postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

